CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders
- Conditions
- Attention Deficit Hyperactivity DisorderSubstance Use Disorders
- Interventions
- Behavioral: cognitive behavioral therapy for treating ADHD symptoms
- Registration Number
- NCT01431235
- Lead Sponsor
- Arkin
- Brief Summary
The purpose of this study is to determine if cognitive behavioral therapy is effective in treating ADHD symptoms in patients with substance use disorders and comorbid ADHD.
- Detailed Description
Attention Deficit Hyperactivity Disorder(ADHD) is an important comorbid condition in patients with substance use disorders (SUD). The prevalence of ADHD in patients with SUD is estimated 23%, and ADHD is associated with an untoward prognosis of SUD. However, adequate treatment programs for patients with ADHD and SUD are not available. Results of medication trials for patients with ADHD and SUD are disappointing, and cognitive behavioral therapy (CBT) has not yet been investigated in this population. In patients with ADHD without comorbid SUD, the results of CBT in randomized trials are positive. The purpose of this study is to investigate if CBT is effective in treating ADHD symptoms in patients with ADHD and SUD.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 184
- substance use disorder
- ADHD
- able to comply with study activities
- severe neurological or psychiatric diseases (for example Parkinson, dementia, psychosis, bipolar depression) which require medication
- unable to read or write Dutch language
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description addiction treatment and ADHD treatment cognitive behavioral therapy for treating ADHD symptoms 10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
- Primary Outcome Measures
Name Time Method self reported ADHD symptoms 6 months Dutch self report list of ADHD symptoms by Kooij and Buitelaar
- Secondary Outcome Measures
Name Time Method TIC-P 6 months health care consumption and production loss in relation to mental health problems
Stroop task 6 months neuropsychological measure
Beck Anxiety Inventory 6 months Self reported anxiety symptoms
Time Line Follow Back method 6 months self-reported alcohol and drug use
EQ-5 6 months Self reported quality of living
urine checks 6 months urine checks on drug use
BART task 6 months neuropsychological task on risk taking behavior
Beck depression inventory 6 months self reported depression symptoms
Tower of London task 6 months neuropsychological task
Trial Locations
- Locations (1)
Arkin
🇳🇱Amsterdam, Netherlands